Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure
Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be ...
Continue Reading →
